21205-Breast Cancer-NA-1270

Breast Cancer

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy (CBYL719C2202)

  • Details

ClinicalTrials.gov ID: NCT04899349
Diagnosis Type: NA
USOR Number:

  • Address

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

Search by practice name, trial titles, indicators and specific disease types.